Moderna, Inc.

MRNA · Nasdaq · ·

Vergelijken

US$ 223,22-3,5%slot 13 nov

Cijfers tot en met 30 september 2026, uit de 10-Q ingediend op 6 november 2026

1W: -12,2%
1M: -5,6%

Aandeel Moderna, Inc. (MRNA) — is dit een goed bedrijf? — InspectStocks

Moderna, Inc.

MRNA · Nasdaq · ·

Vergelijken

US$ 223,22-3,5%slot 13 nov

Cijfers tot en met 30 september 2026, uit de 10-Q ingediend op 6 november 2026

1W: -12,2%
1M: -5,6%

Just reported

Q3 2026 results

From Moderna's results release of 6 november 2026; its quarterly report has since been filed.

Revenue
Actual
US$ 1,31B
+29% y/y
Guided
—
No guide given
EPS, GAAP
Actual
US$ 0,38
Guided
—
No guide given
Operating income, GAAP
Actual
US$ 130M
Guided
—
No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

The full earnings report →

Keep exploring

The themes Moderna is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Samengesteld
Biotech
Door InspectStocks · 19 companies
Drug developers with approved medicines, built mainly on biologic and genetic science.
Koers, 1 jaar
+26,8%
Omzet, 1 jaar
+12,9%
+13
A 8B 4C 5D 1F 1

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 352 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Hoe het geld verdient

COVID-19 vaccine sales, including Spikevax and mNEXSPIKE93%
Payments for manufacturing capacity4%
Government and other grants1%
Collaboration revenue1%
Licensing and royalties1%
RSV vaccine sales, including mRESVIA0%

De omzetaandelen zijn schattingen voor year ended 2025-12-31, geen cijfers uit een ingediend rapport.

Concurreert met

Wat het verkoopt6

Spikevax
A COVID-19 vaccine updated to target circulating virus variants.
mNEXSPIKE
A COVID-19 vaccine that uses a lower mRNA dose than Spikevax and focuses the immune response on key parts of the virus.
mRESVIA
An RSV vaccine for older adults and certain adults at increased risk of severe RSV illness.

Nog 3 tonen

mFLUSIVA
An influenza vaccine approved in the United States and Canada for adults aged 50 and older; commercial sales began in September 2026.
mCOMBRIAX
A vaccine combining protection against influenza and COVID-19, authorized in Europe and Canada for adults aged 50 and older; it had not been commercialized by September 30, 2026.
Intismeran autogene (mRNA-4157)
An investigational personalized cancer treatment designed around mutations in an individual patient's tumor; it is being developed with Merck alongside pembrolizumab.

Wie het koopt4

Wholesalers and distributors, which are the main route for sales in the United States.
Retail pharmacies, health care providers and government entities, which also buy vaccines in the United States.
Governments and international organizations that purchase vaccines.
Governments in the United Kingdom, Canada and Australia, which have multi-year commitments to purchase mRNA products.

Waar het op steunt, en wat het kan breken

Waar het bedrijf van afhangt

1COVID-19 vaccine sales made up 93.1% of revenue in 2025, tying revenue closely to demand for those vaccines.
2Vaccine sales are seasonal and depend on public health recommendations, changes in circulating viruses and whether people choose to get vaccinated.
3Some materials and manufacturing processes rely on single-source suppliers, and the company also uses outside manufacturers and suppliers.
4Intismeran autogene is being developed with Merck, with development costs and potential profits or losses generally shared equally.
5Vaccine products can require cold storage and careful shipping.

Wat er mis kan gaan

1Demand for seasonal vaccines can change with public health recommendations, virus circulation, customer orders and willingness to vaccinate; these changes can affect sales.
2Clinical trials and regulatory reviews may delay or prevent approval of new vaccines and treatments; the influenza vaccine mRNA-1010 had faced a regulatory filing setback before its amended application was accepted for review.
3Manufacturing or supply problems, including supplier interruptions, product-release issues or failures to maintain required shipping and storage conditions, could delay or limit product supply.

Volledige jaarrekening →

Over Moderna, Inc.

Moderna makes vaccines using messenger RNA (mRNA), which gives cells instructions to make a protein that can help prevent or treat disease. It also develops mRNA-based treatments, including a personalized cancer treatment being developed with Merck and treatments for rare inherited diseases. As of September 30, 2026, it had five approved products, though its flu-plus-COVID vaccine had not yet been commercialized.

Hoofdkantoor: Cambridge, Massachusetts
Opgericht in: 2010
Genoteerd aan: Nasdaq
Einde boekjaar: December 31

Gebouwd uit de eigen deponeringen van Moderna, Inc. bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.

Just reported

Q3 2026 results

From Moderna's results release of 6 november 2026; its quarterly report has since been filed.

Revenue
Actual
US$ 1,31B
+29% y/y
Guided
—
No guide given
EPS, GAAP
Actual
US$ 0,38
Guided
—
No guide given
Operating income, GAAP
Actual
US$ 130M
Guided
—
No guide given

The full earnings report →